Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Sutton, Morgan T ^a   Fletcher, David ^a   Ghosh, Santosh K ^b   Weinberg, Aaron ^b   Van Heeckeren, Rolf ^a   Kaur, Sukhmani ^a   Sadeghi, Zhina ^a   Hijaz, Adonis ^a   Reese, Jane ^a,b   Lazarus, Hillard M ^a,b   Lennon, Donald P ^a,b   Caplan, Arnold I ^a,b   Bonfield, Tracey L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC G 418; BETA DEFENSIN 2; BETA DEFENSIN 3; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTAZIDIME; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; TOBRAMYCIN;

ADIPOSE DERIVED STEM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG INFECTION; MALE; MESENCHYMAL STEM CELL; MORBIDITY; MORTALITY; MOUSE; MURINE MODEL; NONHUMAN; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA;

EID: 84958206367     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/5303048     Document Type: Article

References (40)

1. J. F. Chmiel and M. W. Konstan, "Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent," Treatments in Respiratory Medicine, vol. 4, no. 4, pp. 255-273, 2005.
2. D. P. Nichols, M. W. Konstan, and J. F. Chmiel, "Anti-inflammatory therapies for cystic fibrosis-related lung disease," Clinical Reviews in Allergy and Immunology, vol. 35, no. 3, pp. 135-153, 2008.
3. J. F. Chmiel and M. W. Konstan, "Inflammation and anti-inflammatory therapies for cystic fibrosis," Clinics in Chest Medicine, vol. 28, no. 2, pp. 331-346, 2007.
4. D. J. Weiss, M. A. Berberich, Z. Borok et al., "Adult stem cells, lung biology, and lung disease. NHLBI/Cystic Fibrosis Foundation Workshop," Proceedings of the American Thoracic Society, vol. 3, no. 3, pp. 193-207, 2006.
5. A. I. Caplan, "Why are MSCs therapeutic? New data: new insight," Journal of Pathology, vol. 217, no. 2, pp. 318-324, 2009.
6. B. M. Abdallah and M. Kassem, "Human mesenchymal stem cells: from basic biology to clinical applications," Gene Therapy, vol. 15, no. 2, pp. 109-116, 2008.
7. A. I. Caplan and J. E. Dennis, "Mesenchymal stem cells as trophic mediators," Journal of Cellular Biochemistry, vol. 98, no. 5, pp. 1076-1084, 2006.
8. T. L. Bonfield, D. Lennon, S. K. Ghosh, A. M. DiMarino, A. Weinberg, and A. I. Caplan, "Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease," Stem Cell Discovery, vol. 3, no. 2, pp. 139-153, 2013.
9. A. Krasnodembskaya, Y. Song, X. Fang et al., "Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37," Stem Cells, vol. 28, no. 12, pp. 2229-2238, 2010.
10. A. Bragonzi, I. Farulla, M. Paroni et al., "Modelling co-infection of the cystic fibrosis lung by Pseudomonas aeruginosa and Burkholderia cenocepacia reveals influences on biofilm formation and host response," PLoS ONE, vol. 7, no. 12, Article ID e52330, 2012.
11. S. D. Sagel, J. F. Chmiel, and M. W. Konstan, "Sputum biomarkers of inflammation in cystic fibrosis lung disease," Proceedings of the American Thoracic Society, vol. 4, no. 4, pp. 406-417, 2007.
12. T. L. Bonfield, M. T. Nolan, D. P. Lennon, and A. I. Caplan, "Defining human mesenchymal stem cell efficacy in vivo," Journal of Inflammation, vol. 7, article 51, 2010.
13. D. P. Lennon and A. I. Caplan, "Isolation of human marrow-derived mesenchymal stem cells," Experimental Hematology, vol. 34, no. 11, pp. 1604-1605, 2006.
14. Y.-T. Chen, C.-K. Sun, Y.-C. Lin et al., "Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction," Journal of Translational Medicine, vol. 9, article 51, 2011.
15. A. M. LeVine, K. E. Kurak, J. R. Wright et al., "Surfactant protein-a binds group B streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-a-deficient mice," American Journal of Respiratory Cell and Molecular Biology, vol. 20, no. 2, pp. 279-286, 1999.
16. A. Heeckeren, R. Walenga, M. W. Konstan, T. Bonfield, P. B. Davis, and T. Ferkol, "Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa," Journal of Clinical Investigation, vol. 100, no. 11, pp. 2810-2815, 1997.
17. H. A. Cash, D. E. Woods, B. McCullough, W. G. Johanson Jr., and J. A. Bass, "A rat model of chronic respiratory infection with Pseudomonas aeruginosa," American Review of Respiratory Disease, vol. 119, no. 3, pp. 453-459, 1979.
18. N. K. Archer, M. J. Mazaitis, J. W. Costerton, J. G. Leid, M. E. Powers, and M. E. Shirtliff, "Staphylococcus aureus biofilms: properties, regulation, and roles in human disease," Virulence, vol. 2, no. 5, pp. 445-459, 2011.
19. S. K. Ghosh, T. A. Gerken, K. M. Schneider, Z. Feng, T. S. McCormick, and A. Weinberg, "Quantification of human βdefensin-2 and -3 in body fluids: application for studies of innate immunity," Clinical Chemistry, vol. 53, no. 4, pp. 757-765, 2007.
20. H. I. Kawsar, S. K. Ghosh, S. A. Hirsch, H. B. Koon, A. Weinberg, and G. Jin, "Expression of human beta-defensin-2 in intratumoral vascular endothelium and in endothelial cells induced by transforming growth factor beta," Peptides, vol. 31, no. 2, pp. 195-201, 2010.
21. R. Simon, M. D. Radmacher, and K. Dobbin, "Design of studies using DNA microarrays," Genetic Epidemiology, vol. 23, no. 1, pp. 21-36, 2002.
22. B. A. Simon, R. B. Easley, D. N. Grigoryev et al., "Microarray analysis of regional cellular responses to local mechanical stress in acute lung injury," American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 291, no. 5, pp. L851-L861, 2006.
23. M. L. Drumm, M. W. Konstan, M. D. Schluchter et al., "Genetic modifiers of lung disease in cystic fibrosis," The New England Journal of Medicine, vol. 353, no. 14, pp. 1443-1453, 2005.
24. M. D. Schluchter, M. W. Konstan, M. L. Drumm, J. R. Yankaskas, and M. R. Knowles,"Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data," American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 7, pp. 780-786, 2006.
25. A. D. Guerra, D. A. Cantu, J. T. Vecchi, W. E. Rose, P. Hematti, and W. J. Kao, "Mesenchymal stromal/stem cell and minocycline-loaded hydrogels inhibit the growth of Staphylococcus aureus that evades immunomodulation of blood-derived leukocytes," The AAPS Journal, vol. 17, no. 3, pp. 620-630, 2015.
26. M. A. Matthay, A. Goolaerts, J. P. Howard, and J. W. Lee, "Mesenchymal stem cells for acute lung injury: preclinical evidence," Critical Care Medicine, vol. 38, no. 10, pp. S569-S573, 2010.
27. M. A. Kovach, M. N. Ballinger, M. W. Newstead et al., "Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in gram-negative bacterial pneumonia," Journal of Immunology, vol. 189, no. 1, pp. 304-311, 2012.
28. A. Lever and I. Mackenzie, "Sepsis: definition, epidemiology, and diagnosis," British Medical Journal, vol. 335, no. 7625, pp. 879-883, 2007.
29. L. M. Napolitano, "Immune stimulation in sepsis: to be or not to be?" Chest, vol. 127, no. 6, pp. 1882-1885, 2005.
30. K. Lyn-Kew and T. J. Standiford, "Immunosuppression in sepsis," Current Pharmaceutical Design, vol. 14, no. 19, pp. 1870-1881, 2008.
31. M. Golec, "Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide," Annals of Agricultural and Environmental Medicine, vol. 14, no. 1, pp. 1-4, 2007.
32. G. Sakoulas, K. Guram, K. Reyes, V. Nizet, and M. Zervos, "Human cathelicidin LL-37 resistance and increased daptomycin MIC in methicillin-resistant Staphylococcus aureus strain USA600 (ST45) are associated with increased mortality in a hospital setting," Journal of Clinical Microbiology, vol. 52, no. 6, pp. 2172-2174, 2014.
33. N. Strempe, A. Neidig, M. Nusser et al., "Human host defense peptide LL-37 stimulates virulence factor production and adaptive resistance in Pseudomonas aeruginosa," PLoS ONE, vol. 8, no. 12, Article ID e82240, 2013.
34. A. Scott, S. Weldon, P. J. Buchanan et al., "Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo," PLoS ONE, vol. 6, no. 10, Article ID e26525, 2011.
35. K. L. Brown, G. F. T. Poon, D. Birkenhead et al., "Host defense peptide LL-37 selectively reduces proinflammatory macrophage responses," Journal of Immunology, vol. 186, no. 9, pp. 5497-5505, 2011.
36. P.Méndez-Samperio, "The human cathelicidin hCAP18/LL-37: a multifunctional peptide involved in mycobacterial infections," Peptides, vol. 31, no. 9, pp. 1791-1798, 2010.
37. J. J. Auletta, S. K. Eid, P. Wuttisarnwattana et al., "Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation," STEM CELLS, vol. 33, no. 2, pp. 601-614, 2014.
38. C. I.-U. Chen, S. Schaller-Bals, K. P. Paul, U. Wahn, and R. Bals, "β-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis," Journal of Cystic Fibrosis, vol. 3, no. 1, pp. 45-50, 2004.
39. D. S. Zagoura, O. Trohatou, V. Bitsika et al., "AF-MSCs fate can be regulated by culture conditions," Cell Death and Disease, vol. 4, article e571, 2013.
40. E. Soleymaninejadian, K. Pramanik, and E. Samadian, "Immunomodulatory properties of mesenchymal stem cells: cytokines and factors," American Journal of Reproductive Immunology, vol. 67, no. 1, pp. 1-8, 2012.